Matrix M™ adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4 + T cell responses in man

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 8, 2014, Pages 2408-2416

  Pedersen, Gabriel K ^a   Sjursen, Haakon ^a,b   Nøstbakken, Jane K ^a   Jul Larsen, Åsne ^a   Hoschler, Katja ^c   Cox, Rebecca J ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

CD4; CD8; Cytokine; H5N1; Human; Influenza; Matrix M; Th1; Th2; Vaccine

Indexed keywords

INFLUENZA VACCINE; CYTOKINE; IMMUNOLOGICAL ADJUVANT; VIROSOME VACCINE;

ADJUVANT THERAPY; ADULT; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS REACTION; CYTOKINE RESPONSE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; MICRONEUTRALISATION; OPEN STUDY; PHASE 1 CLINICAL TRIAL; SERODIAGNOSIS; SINGLE RADIAL HEMOLYSIS ASSAY; TH1 CELL; TH2 CELL; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; FEMALE; IMMUNOLOGY; MALE; NORMAL HUMAN; SECRETION (PROCESS);

ADJUVANTS, IMMUNOLOGIC; ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MALE; TH1 CELLS; TH2 CELLS; VACCINES, VIROSOME;

EID: 84908461841     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29583     Document Type: Article

References (45)

1. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, Zhong G, Hanson A, Katsura H, Watanabe S, et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 2012; 486:420-8; PMID:22722205axi
2. Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, Munster VJ, Sorrell EM, Bestebroer TM, Burke DF, Smith DJ, et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 2012; 336:1534-41; PMID:22723413; http://dx.doi.org/10.1126/science.1213362
3. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36-44; PMID:22032844; http://dx.doi.org/10.1016/S1473-3099(11)70295-X
4. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010; CD001269; PMID:20614424
5. McKinstry KK, Strutt TM, Swain SL. The potential of CD4 T-cell memory. Immunology 2010; 130:1-9; PMID:20331470; http://dx.doi.org/10.1111/j.1365-2567.2010.03259.x
6. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983; 309:13-7; PMID:6602294; http://dx.doi.org/10.1056/NEJM198307073090103
7. Stambas J, Guillonneau C, Kedzierska K, Mintern JD, Doherty PC, La Gruta NL. Killer T cells in influenza. Pharmacol Ther 2008; 120:186-96; PMID:18801385; http://dx.doi.org/10.1016/j.pharmthera.2008.08.007
8. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012; 18:274-80; PMID:22286307; http://dx.doi.org/10.1038/nm.2612
9. Moran TM, Park H, Fernandez-Sesma A, Schulman JL. Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J Infect Dis 1999; 180:579-85; PMID:10438342; http://dx.doi.org/10.1086/314952
10. Graham MB, Braciale VL, Braciale TJ. Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection. J Exp Med 1994; 180:1273-82; PMID:7931062; http://dx.doi.org/10.1084/jem.180.4.1273
11. Duvall MG, Precopio ML, Ambrozak DA, Jaye A, McMichael AJ, Whittle HC, Roederer M, Rowland-Jones SL, Koup RA. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol 2008; 38:350-63; PMID:18200635; http://dx.doi.org/10.1002/eji.200737768
12. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13:843-50; PMID:17558415; http://dx.doi.org/10.1038/nm1592
13. Forbes EK, Sander C, Ronan EO, McShane H, Hill AV, Beverley PC, Tchilian EZ. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 2008; 181:4955-64; PMID:18802099; http://dx.doi.org/10.4049/jimmunol.181.7.4955
14. Pedersen G, Major D, Roseby S, Wood J, Madhun AS, Cox RJ. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza Other Respir Viruses 2011; 5:426-37; PMID:21668670; http://dx.doi.org/10.1111/j.1750-2659.2011.00256.x
15. Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 2007; 81:8468-76; PMID:17553885; http://dx.doi.org/10.1128/JVI.00228-07
16. Tangye SG, Ferguson A, Avery DT, Ma CS, Hodgkin PD. Isotype switching by human B cells is division-associated and regulated by cytokines. J Immunol 2002; 169:4298-306; PMID:12370361; http://dx.doi.org/10.4049/jimmunol.169.8.4298
17. Hasbold J, Corcoran LM, Tarlinton DM, Tangye SG, Hodgkin PD. Evidence from the generation of immunoglobulin G-secreting cells that stochastic mechanisms regulate lymphocyte differentiation. Nat Immunol 2004; 5:55-63; PMID:14647274; http://dx.doi.org/10.1038/ni1016
18. Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 2008; 26:2350-9; PMID:18400340; http://dx.doi.org/10.1016/j.vaccine.2008.02.063
19. Moran TM, Isobe H, Fernandez-Sesma A, Schulman JL. Interleukin-4 causes delayed virus clearance in influenza virus-infected mice. J Virol 1996; 70:5230-5; PMID:8764032
20. Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, Brown SA, Makarova N, Perez DR, Macdonald GH, McCullers JA. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 2006; 13:981-90; PMID:16960108; http://dx.doi.org/10.1128/CVI.00156-06
21. Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, Nuti S, Tavarini S, Sammicheli C, Hilbert AK, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A 2009; 106:3877-82; PMID:19237568; http://dx.doi.org/10.1073/pnas.0813390106
22. Moris P, van der Most R, Leroux-Roels I, Clement F, Dramé M, Hanon E, Leroux-Roels GG, Van Mechelen M. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011; 31:443-54; PMID:21174144; http://dx.doi.org/10.1007/s10875-010-9490-6
23. Madhun AS, Haaheim LR, Nilsen MV, Cox RJ. Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine 2009; 27:7367-76; PMID:19781678; http://dx.doi.org/10.1016/j.vaccine.2009.09.044
24. Cox RJ, Pedersen G, Madhun AS, Svindland S, Sævik M, Breakwell L, Hoschler K, Willemsen M, Campitelli L, Nøstbakken JK, et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine 2011; 29:8049-59; PMID:21864624; http://dx.doi.org/10.1016/j.vaccine.2011.08.042
25. Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, Goudsmit J, Cox RJ. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis 2012; 206:158-66; PMID:22551811; http://dx.doi.org/10.1093/infdis/jis330
26. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260:547-9; PMID:8097338; http://dx.doi.org/10.1126/science.8097338
27. Shi Y, Liu CH, Roberts AI, Das J, Xu G, Ren G, Zhang Y, Zhang L, Yuan ZR, Tan HS, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res 2006; 16:126-33; PMID:16474424; http://dx.doi.org/10.1038/sj.cr.7310017
28. Huang FF, Barnes PF, Feng Y, Donis R, Chroneos ZC, Idell S, Allen T, Perez DR, Whitsett JA, Dunussi-Joannopoulos K, et al. GM-CSF in the lung protects against lethal influenza infection. Am J Respir Crit Care Med 2011; 184:259-68; PMID:21474645; http://dx.doi.org/10.1164/rccm.201012-2036OC
29. Magnusson SE, Reimer JM, Karlsson KH, Lilja L, Bengtsson KL, Stertman L. Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine 2013; 31:1725-33; PMID:23384754; http://dx.doi.org/10.1016/j.vaccine.2013.01.039
30. Pichichero ME. Improving vaccine delivery using novel adjuvant systems. Hum Vaccin 2008; 4:262-70; PMID:18398303; http://dx.doi.org/10.4161/hv.4.4.5742
31. Heijmans S, De Meulemeester M, Reynders P, Giet D, Demanet E, Devresse PY, Icardi G, Dramé M, Roman F, Gillard P. Immunogenicity profile of a 3.75-mug hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis 2011; 203:1054-62; PMID:21450995; http://dx.doi.org/10.1093/infdis/jiq174
32. Pathirana RD, Bredholt G, Akselsen PE, Pedersen GK, Cox RJA. A(H1N1)pdm09 vaccination of health care workers: improved immune responses in low responders following revaccination. J Infect Dis 2012; 206:1660-9; PMID:22969149; http://dx.doi.org/10.1093/infdis/jis589
33. Jul-Larsen A˚, Madhun AS, Brokstad KA, Montomoli E, Yusibov V, Cox RJ. The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants. Hum Vaccin Immunother 2012; 8:653-61; PMID:22634440; http://dx.doi.org/10.4161/hv.19503
34. Roman F, Clément F, Dewé W, Walravens K, Maes C, Willekens J, De Boever F, Hanon E, Leroux-Roels G. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol 2011; 18:835-43; PMID:21450978; http://dx.doi.org/10.1128/CVI.00480-10
35. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010; 10:170-81; PMID:20154735; http://dx.doi.org/10.1038/nri2711
36. Lee LY, Ha LA, Simmons C, de Jong MD, Chau NV, Schumacher R, Peng YC, McMichael AJ, Farrar JJ, Smith GL, et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 2008; 118:3478-90; PMID:18802496
37. Kabilan L, Andersson G, Lolli F, Ekre HP, Olsson T, Troye-Blomberg M. Detection of intracellular expression and secretion of interferon-gamma at the single-cell level after activation of human T cells with tetanus toxoid in vitro. Eur J Immunol 1990; 20:1085-9; PMID:2113474; http://dx.doi.org/10.1002/eji.1830200521
38. Jung T, Schauer U, Heusser C, Neumann C, Rieger C. Detection of intracellular cytokines by flow cytometry. J Immunol Methods 1993; 159:197-207; PMID:8445253; http://dx.doi.org/10.1016/0022-1759(93)90158-4
39. Gijzen K, Liu WM, Visontai I, Oftung F, van der Werf S, Korsvold GE, Pronk I, Aaberge IS, Tütto A, Jankovics I, et al. Standardization and validation of assays determining cellular immune responses against influenza. Vaccine 2010; 28:3416-22; PMID:20206285; http://dx.doi.org/10.1016/j.vaccine.2010.02.076
40. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, Höschler K, Saville M, Vogel FR, Barclay W, et al. A phase I clinical trial of a PER. C6 cell grown influenza H7 virus vaccine. Vaccine 2009; 27:1889-97; PMID:19368768; http://dx.doi.org/10.1016/j.vaccine.2009.01.116
41. Pedersen G, Halstensen A, Sjursen H, Naess A, Kristoffersen EK, Cox RJ. Pandemic influenza vaccination elicits influenza-specific CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports. Scand J Immunol 2011; 74:210-8; PMID:21438900; http://dx.doi.org/10.1111/j.1365-3083.2011.02561.x
42. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, Fukuda K, Cox NJ, Katz JM. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-43; PMID:10074505
43. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937-43; PMID:11425416; http://dx.doi.org/10.1016/S0140-6736(00)05066-2
44. Stephenson I, Wood JM, Nicholson KG, Zambon MC. Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. J Med Virol 2003; 70:391-8; PMID:12767002; http://dx.doi.org/10.1002/jmv.10408
45. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, di Giovanni P, Sticchi L, Gentile C, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 2009; 4:e4384; PMID:19197383; http://dx.doi.org/10.1371/journal.pone.0004384